Ignite Creation Date:
2024-05-06 @ 4:06 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04877717
Status:
UNKNOWN
Last Update Posted:
2021-10-04
First Post:
2021-04-27
Brief Title:
A Study of SHR-A1904 in Patients With Advanced Solid Cancer
Sponsor:
Shanghai Hengrui Pharmaceutical Co Ltd
Organization:
Shanghai Hengrui Pharmaceutical Co Ltd
Study Overview
Official Title:
An Open-Label Single-Arm Multi-Center Phase I Clinical Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of SHR-A1904 in Patients With Advanced Solid Tumors
Status:
UNKNOWN
Status Verified Date:
2021-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is being conducted to assess the safety and tolerability of SHR-A1904 in patients with advanced solid cancer and to determine the dose-limiting toxicity DLT maximum tolerated dose MTD and recommended phase II dose RP2D of SHR-A1904
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None